What is HC Wainwright’s Forecast for CHRN Q2 Earnings?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) – Investment analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for ChronoScale Corporation Common Stock in a note issued to investors on Monday, June 15th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.06) per share for the quarter. HC Wainwright also issued estimates for ChronoScale Corporation Common Stock’s Q3 2026 earnings at ($0.02) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.10) EPS, FY2027 earnings at ($0.06) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.14 EPS.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last posted its earnings results on Tuesday, April 28th. The company reported ($2.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($2.01). ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The company had revenue of $2.14 million during the quarter, compared to the consensus estimate of $4.29 million.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a report on Friday, March 27th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, ChronoScale Corporation Common Stock has an average rating of “Reduce” and a consensus price target of $6.00.

ChronoScale Corporation Common Stock Trading Up 0.3%

NASDAQ CHRN opened at $25.75 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.03 and a debt-to-equity ratio of 0.25. The business has a fifty day simple moving average of $15.87 and a 200 day simple moving average of $11.31. ChronoScale Corporation Common Stock has a 12 month low of $2.73 and a 12 month high of $28.20. The firm has a market capitalization of $91.67 million, a P/E ratio of -4.79 and a beta of 1.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Roble Belko & Company Inc grew its position in shares of ChronoScale Corporation Common Stock by 104.5% during the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock valued at $25,000 after acquiring an additional 1,195 shares during the period. Virtu Financial LLC bought a new stake in shares of ChronoScale Corporation Common Stock in the 3rd quarter worth approximately $57,000. Shay Capital LLC purchased a new position in ChronoScale Corporation Common Stock in the third quarter valued at approximately $67,000. Geode Capital Management LLC lifted its stake in ChronoScale Corporation Common Stock by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after purchasing an additional 10,281 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in ChronoScale Corporation Common Stock during the third quarter valued at $198,000. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.